August 2, 2017 News by Patricia Inacio, PhD 24 People in Phase 1 Trial Focusing on Psoriasis Have Received KY1005, Which Is Also an MS Therapy Twenty-four people have now received the multiple sclerosis and psoriasis therapy KY1005 in a Phase 1 clinical trial, according to its developer,Ā Kymab. The Cambridge, England, company createsĀ human antibody drugs for autoimmune diseases. The trial will focus on KY1005 as a psoriasis therapy, although its mechanism of action should work…